Livmarli

Chemical Namemaralixibat
Dosage FormSolution (oral; 9.5 mg/mL)
Drug ClassInhibitors
SystemDigestive
CompanyMirum Pharmaceuticals
Approval Year2021

Indication

  • For the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 1 year of age and older
Last updated on 3/15/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Livmarli (maralixibat) Prescribing Information.2021Mirum Pharmaceuticals Inc., Foster City, CA